Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991795 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 19,271
- Enrollment target
NCT01991795 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 19,271 participants.
The verdict
NCT01991795, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19,271 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
Interventions
- DRUG Ticagrelor 60 mg
- DRUG Ticagrelor placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,271 participants |
| Start Date | 2014-02-10 |
| Est. Completion | 2019-01-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01991795
The ClinicalTrials.gov registry entry for NCT01991795 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19,271 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ticagrelor 60 mg is the first listed.
NCT01991795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01991795 about?
NCT01991795 is a clinical study titled "A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
What is the current status of trial NCT01991795?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19,271 participants. The study started on 2014-02-10. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT01991795?
The interventions under investigation include: Ticagrelor 60 mg (DRUG), Ticagrelor placebo (DRUG).
Who is sponsoring clinical trial NCT01991795?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.